Japan Intravenous Iron Drugs Market Size & Outlook
Japan intravenous iron drugs market, 2018-2030 (US$M)
Related Markets
Japan intravenous iron drugs market highlights
- The Japan intravenous iron drugs market generated a revenue of USD 51.8 million in 2023 and is expected to reach USD 216.6 million by 2030.
- The Japan market is expected to grow at a CAGR of 22.7% from 2024 to 2030.
- In terms of segment, ferric carboxymaltose was the largest revenue generating product in 2023.
- Ferric Carboxymaltose is the most lucrative product segment registering the fastest growth during the forecast period.
Intravenous iron drugs market data book summary
| Market revenue in 2023 | USD 51.8 million |
| Market revenue in 2030 | USD 216.6 million |
| Growth rate | 22.7% (CAGR from 2023 to 2030) |
| Largest segment | Ferric carboxymaltose |
| Fastest growing segment | Ferric Carboxymaltose |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Iron Dextran, Iron Sucrose, Ferric Carboxymaltose |
| Key market players worldwide | AbbVie Inc, Civitas Resources Inc Ordinary Shares, Daiichi Sankyo Co Ltd, Sanofi SA, CSL Ltd, COSMOS Pharmaceutical Corp, Zydus Lifesciences, Rockwell Medical Inc |
Other key industry trends
- In terms of revenue, Japan accounted for 1.7% of the global intravenous iron drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan intravenous iron drugs market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 151.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Iron Drugs Market Scope
Intravenous Iron Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan intravenous iron drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous iron drugs market will help companies and investors design strategic landscapes.
Ferric carboxymaltose was the largest segment with a revenue share of 25.87% in 2023. Horizon Databook has segmented the Japan intravenous iron drugs market based on iron dextran, iron sucrose, ferric carboxymaltose covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing prevalence of target diseases and growing geriatric population, which increase the prevalence of various diseases, along with associated risks such as anemia, are factors expected to drive the market over the forecast period. For instance, the rising prevalence of HIV/AIDS in Japan is anticipated to boost market growth during the forecast period.
According to WHO, around 976 adults were diagnosed with HIV (938 males & 38 females), and about 413 adults were diagnosed with AIDS (375 males & 38 females). Among the 976 cases of HIV/AIDS, 152 were non-Japanese individuals and 824 were Japanese. Out of the 976 HIV cases, 126 males were infected due to heterosexual contact.
About 123,432 specimens were tested for HIV antibodies in 2017 and 118,005 in 2016. Growth in incidence of HIV in Japan may lead to an increase in cases of HIV-induced anemia, which is anticipated to fuel rapid market growth.
Reasons to subscribe to Japan intravenous iron drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan intravenous iron drugs market databook
-
Our clientele includes a mix of intravenous iron drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan intravenous iron drugs market , including forecasts for subscribers. This country databook contains high-level insights into Japan intravenous iron drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan intravenous iron drugs market size, by product, 2018-2030 (US$M)
Japan Intravenous Iron Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
